Mark Leong – Executive Chairman – Osteopore (ASX:OSX) is a Singapore-headquartered corporation poised to be a leading medical device company in the region. It is involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery use.
Copyright 2023 – Finance News Network
Source: Finance News Network
31 May 2023 - European Metal Holdings Limited (ASX:EMH) Executive Chairman Keith Coughlan discusses the European demand for lithium and the scale of the company's Cinovec project.
Read More31 Oct 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the market outlook, giving general advice on investment implications.
Read More10 Oct 2023 - Cameron Perks - Principal Analyst - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Read More06 Jul 2023 - Tamboran Resources Limited (ASX:TBN) Managing Director and CEO Joel Riddle discusses the company's recent capital raise, the drilling timeline, and agreements with APA Group, Clean Energy Fuels Australia, BP and Shell.
Read More28 May 2021 - Beston Global Foods Limited (ASX:BFC) CFO and Acting CEO Darren Flew discusses the company's FY21 results, guidance and strategy, and provides an update on the company's lactoferrin expansion project at its Jervois dairy in South Australia.
Read More23 Nov 2023 - WT Financial Group (ASX:WTL) expands its footprint with the acquisition of Millennium3. Founder and Managing Director Keith Cullen discusses synergies and growth strategies in the dynamic financial advisory sector.
Read More15 Nov 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Dr Michael Baker provides an update on the company.
Read More17 May 2024 - Dotz Nano Limited (ASX:DTZ) Director Glenn Kelly discusses the carbon capture market and the different technologies available.
Read More23 Sep 2019 - Lake Resources Limited (ASX:LKE) Managing Director, Steve Prominitz provides an update on progress across the company's project portfolio.
Read More25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.
Read More
